News | Radiation Therapy | March 09, 2016

Study Suggests Partial Breast Radiation Sufficient for Early Breast Cancer

European trial finds similar local control, reduced toxicity with intensity modulated radiotherapy to the tumor bed only

whole breast radiotherapy, early breast cancer, IMRT, European study

March 9, 2016 — Radiotherapy to the whole breast is standard treatment after breast-conserving surgery for women with early breast cancer, even those who have a low risk of the disease returning in the breast (local relapse). However, whole breast radiotherapy can cause changes in the appearance of the breast, which may also be firmer and tender to the touch, resulting in psychological distress.

"So we considered it important to set up a trial to answer the question: Is full dose radiotherapy to the whole breast needed in patients with low risk early breast cancer?," Charlotte Coles, M.D., consultant clinical oncologist at Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom, told the 10th European Breast Cancer Conference (EBCC-10) Wednesday. "One group of women received standard full dose radiotherapy to the whole breast. A second group received standard full dose to breast tissue closest to where the lump appears and a slightly lower dose further away. A third group received standard full dose radiotherapy to breast tissue closest to where the lump appears but no radiotherapy dose apart from this.

"We found after five years that rates of local relapse (the reappearance of a cancer after treatment in the breast where it was originally detected) were very low in all treatment groups, including those receiving less radiotherapy. Moderate and marked changes in normal breast tissue were also low across all groups. Follow-up is ongoing and ten-year local recurrence rates will be reported at a later stage," she said.

Coles and colleagues from 30 radiotherapy centers across the U.K., led by researchers at The Institute of Cancer Research, London, recruited 2,018 patients aged over 50 who had had breast conservation surgery for invasive early breast cancer tumors measuring less than 3 cm at their largest point. They were randomized into three groups: Six hundred seventy-five had whole breast radiotherapy at the standard dose of 40 Gy to the whole breast (the control group), 674 had 40 Gy to the tumor bed and 36 Gy to the rest of the breast, and 669 had 40 Gy to the tumor bed only; the latter two "test" groups being two ways of focusing radiotherapy to the tumor bed and giving lower or no dose to the rest of the breast.

All patients were treated with intensity modulated radiotherapy (IMRT), a technique that can deliver an even dose of radiation, thus minimizing the chances of hotspots of unwanted high doses and reducing the cosmetic problems that can occur after breast radiotherapy. The characteristics of the three groups were very similar and the average age was 63 years.

"Five years after treatment, we found very low rates of local recurrence and minimal side effects across all the groups. We also found evidence of benefit to patients in the 'test' groups in terms of satisfaction with overall breast appearance as reported by patients themselves, particularly for those receiving no radiotherapy outside the tumor bed. However, we intend to continue to follow up the trial patients for at least ten years because we know that cancer recurrence can still occur more than five years after completion of treatment. It may be that no dose outside the tumor bed (partial breast radiotherapy) is sufficient for many patients, but some dose at a lower level than that given to the tumor bed is more appropriate for others," said Coles.

The researchers believe that, in addition to minimizing hotspots, the use of radiotherapy focused around the tumor bed with IMRT benefits patients because it spares part of the breast from either a full or any dose to the rest of the breast.

This form of IMRT is a simple, quick and cheap technique, which can be carried out with all standard radiotherapy equipment. It is now standard practice in the majority of radiotherapy centers Europe.

"The radiotherapy beams have a glancing orientation that covers the breast but limits the dose to the lung and also the heart in left-sided breast cancers. There is, therefore, no concern about a higher volume of low-dose radiation to normal tissue, which is sometimes a worry in more complex types of IMRT," said Coles.

In addition to the ten-year follow-up, the researchers also intend to investigate in more depth the patient-reported outcome measures (PROMS). In addition to specific questions about the patient's breast and related symptoms, where outcomes have already been shown to be at least as good if not better than with whole breast radiotherapy, they also include more general questions about quality of life. "This is another area where we would expect to see better results from the test groups," said Coles.

"We hope that the evidence of benefit we have shown in this trial will bring about a change in practice worldwide, and enable very many more women with early breast cancer to undergo this treatment. At a time when breast cancer mortality rates are falling and more women are surviving their cancer, we believe it is particularly important to keep any treatment toxicity to the absolute minimum," she concluded.

Chair of the conference, Prof. Fatima Cardoso, director of the Breast Unit of the Champalimaud Clinical Centre in Lisbon, Portugal, said: "Over-treatment is a problem in cancers with a low risk of recurrence. This important study shows that, at least at five years follow-up, radiotherapy focused around the tumor bed with the IMRT technique provides as good local control as whole breast radiation and is associated with fewer side effects. This may, indeed, lead to a change in practice with benefits for patients and society, since it will also reduce costs. Longer follow-up is needed, however, since low-risk breast cancer has a long natural history."

For more information: www.ecco-org.eu

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...